Mylan (MYL): Cutting Ests On Continued Headline Risk - RBC
- Apple (AAPL) Tops Q4 EPS by 2c; Issues Solid Outlook
- Wall Street slips on earnings; Apple falls late after results
- Chipotle Mexican Grill (CMG) Posts Q3 EPS of $0.27; Comps Miss Views; Additional Stock Buyback Approved
- Pandora (P) Misses Q3 EPS by 1c, Q4 Revenue Guidance Falls Short
- After-Hours Movers 10/25: (OGXI) (AKAM) (VRTX) Higher; (EW) (NUVA) (CMG) (AAPL) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
RBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of Mylan (NASDAQ: MYL) but cautioned investors that headline risk is likely to remain with the company for some time.
The analyst stated "Epipen headline is not going away with House Oversight and Government Reform Committee investigation underway despite moves by MYL to appease critics. MYL has now announced (i) that "net pricing" for Epipen had been $274 (with channel realizing the remaining $334 of $608 list price) (ii) on 8/25 expansion of its patient access programs via savings cards of up to $300 and doubling of eligibility for the patient assistance program and (iii) on 8/29 that it will be introducing a generic Epipen at a "list price" of $300. While generic share and effective "net" pricing is unclear, we are lowering our gross-to-net assumptions which drives our EPS lower by $0.22 and $0.15 in 2017-18 (-4% and -2%) and we are lowering our price target to $48. Overall, each 10% hit to Epipen revenue impacts EPS by $0.14 or 3%."
The price target is cut to $48 from $52.
Shares of Mylan closed at $39.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Starts Mylan (MYL) at Buy
- Visa (V) PT Raised to $97 at UBS on Solid Q4
- UBS Raises Price Target on Zions Bancorp (ZION) to $29 Following 3Q EPS Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!